This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TGFB1I1 · Western blot design guide
TGFB1I1 Western Blot Planning Guide
Plan a TGFB1I1 Western blot around the catalog-observed 49.8 kDa band, image-backed A04630-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
TGFB1I1 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 49.8 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Cervix | |
| Negative control | Epididymis |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 49.8 kDa |
| ⓘ | Localization | Cell junction, focal adhesion / Nucleus matrix |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated TGFB1I1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adipose tissue |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A04630-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected TGFB1I1 Western Blot Band Size?
Use the product-observed 49.8 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 49.8 kDa | Matches the authoritative product WB observation. |
| 49.8 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected TGFB1I1 appearancePlan around 49.8 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 49.8 kDa; use this as the primary experimental expectation. |
| Calculated mass | 49.8 kDa from UniProt O43294; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A04630-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 49.8 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing TGFB1I1 band
A04630-2 · TGFB1I1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for TGFB1I1 Western blot
🧪Use Cervix as the first positive-control candidate and Epididymis as the HPA Not detected negative candidate.
Positive control: Cervix (Medium)
Negative control: Epididymis (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for TGFB1I1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cervix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Adipose tissue | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced TGFB1I1 Western Blot Tips
Deeper troubleshooting and optimisation questions for TGFB1I1, answered from its protein features.
Which band should guide the blot?
Use 49.8 kDa, the observation attached to the authoritative A04630-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 49.8 kDa expectation.
Which positive control should I start with?
Start with Cervix, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Epididymis as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for TGFB1I1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A04630-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
TGFB1I1 Western Blot Reagents
Human-reactive TGFB1I1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-HIC5/TGFB1I1 Antibody Picoband®
Cat # A04630-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt O43294
- Human Protein Atlas — TGFB1I1
- A04630-2 product record
- PMC4350345 — Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas (Oncotarget, 2014)
- PMC13419796 — P95-HER2 promotes metastatic progression by biasing MRTFA dependent signaling (bioRxiv : the preprint server for biology, 2026)
- PMC6470438 — Label-Free LC-MS/MS Proteomics Analyses Reveal Proteomic Changes Accompanying MSTN KO in C2C12 Cells (BioMed research international, 2019)